BPC 157 , or Body Protection Compound 157, is a short-chain peptide consisting of 15 amino acids
insulin dose at GLP-1RA initiation was only decreased if HbA1c was below 7.5% ( Our current practice is to consider a ~20% bolus insulin decrease and a ~10% basal insulin decrease before GLP-1RA initiation, although prior A1c, risk of hypoglycemia, potential risk of ketosis due to reduced insulin doses, as well as other patient-specific factors should guide the final insulin dose changes
As dozens of novel agents currently under study seek new indications, the question arises of whether the traditional practice of two confirmatory trials for every indication expansion remains justified, especially when database study emulations that benchmark against previously conducted, closely related reference trials have yielded aligned results 33,34
Following the last treatment, the mice had been fasted overnight but had access to water
High-fat diet mouse model receiving L-glucose supplementations propagates liver injury
If a patient cannot tolerate a dose increases, the escalation may be delayed